

**BRIEF COMMUNICATION**

Movement Disorders Resulting From Bilateral Basal Ganglia Lesions in End-Stage Kidney Disease: A Systematic Review

Kah Hui Yap,^{1*} Nurul Husna Baharudin,^{1*} Abdul Halim Abdul Gafor,¹ Rabani Remli,¹ Shen-Yang Lim,² Wan Asyraf Wan Zaidi,¹ Shahrul Azmin,¹ Shahizon Azura Mohamed Mukari,³ Raihanah Abdul Khalid,⁴ Norlinah Mohamed Ibrahim¹

¹Department of Medicine, UKM Medical Center, Kuala Lumpur, Malaysia

²Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

³Department of Radiology, UKM Medical Center, Kuala Lumpur, Malaysia

⁴Department of Neurology, Assunta Hospital, Selangor, Malaysia

ABSTRACT

Objective The basal ganglia (BG) are susceptible to fluctuations in blood urea levels, sometimes resulting in movement disorders. We described patients with end-stage kidney disease (ESKD) presenting with movement disorders associated with bilateral BG lesions on imaging.

Methods We report four patients and systematically reviewed all published cases of ESKD presenting with movement disorders and bilateral BG lesions (EBSCOhost and Ovid).

Results Of the 72 patients identified, 55 (76.4%) were on regular dialysis. Parkinsonism was the most common movement disorder ($n = 39$; 54.2%), followed by chorea ($n = 24$; 33.3%). Diabetes mellitus ($n = 51$; 70.8%) and hypertension ($n = 16$; 22.2%) were the most common risk factors. Forty-three (59.7%) were of Asian ethnicity. Complete clinical resolution was reported in 17 (30.9%) patients, while 38 (69.1%) had incomplete clinical resolution with relapse. Complete radiological resolution occurred in 14 (34.1%) patients.

Conclusion Movement disorders associated with BG lesions should be recognized as a rare and potentially reversible metabolic movement disorder in patients with ESKD.

Keywords Basal ganglia; Chorea; End-stage kidney disease; Magnetic resonance imaging; Parkinsonism.

Movement disorders associated with bilateral basal ganglia (BG) lesions in patients with end-stage kidney disease (ESKD) were first reported in three Korean patients in 1998. Since then, similar cases presenting with either hyperkinetic movement disorder or parkinsonism have been described, although it remains relatively rare.¹ A longitudinal study over two years involving seventy Middle Eastern ESKD patients identified this syndrome

in only three (4.3%) patients.²

Here, we describe four patients with ESKD on dialysis presenting with movement disorder and bilateral BG lesions and conducted a systematic review of this syndrome focusing on its phenomenology and prognosis.

Received: December 15, 2021 Revised: February 15, 2022 Accepted: February 19, 2022

Corresponding author: Norlinah Mohamed Ibrahim, MRCPi

Department of Medicine, UKM Medical Center, 56000 Kuala Lumpur, Malaysia / Tel: +603-91456083/+603-91457312 / E-mail: norlinah@ppukm.ukm.edu.my

*This authors contributed equally to this work.

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

MATERIALS & METHODS

We described four cases and performed a literature search in EBSCOhost and Ovid using Medical Subject Headings (MeSH) terms with no language restrictions (September 9, 2021): [(“renal disease” OR “uraemia”) AND (“basal ganglia” OR “striatal” OR “putaminal” OR “caudate” OR “hyperintensity” OR “hypodensity”) AND (“movement disorder” OR “chorea” OR “Parkinsonism”)]. This study was approved by the Research Ethics Committee of UKM (JEP-2021-689).

RESULTS

Of the 1,033 articles screened, 38 articles fulfilled our search term criteria, yielding a total of 72 patients (Supplementary Figure 1 in the online-only Data Supplement), and details were outlined in Supplementary Table 1 (in the online-only Data Supplement). Approximately 43 (59.7%) patients were Asians. The most common premorbid/comorbid conditions were type 2 diabetes mellitus (T2DM) ($n = 51$; 70.8%), followed by hypertension ($n = 16$; 22.2%). Parkinsonism was the most common movement disorder ($n = 39$; 54.2%), followed by chorea ($n = 24$; 33.3%) (Table 1). Most patients were on regular dialysis before the onset of the movement disorder ($n = 55$; 76.4%). Therapy was mainly supportive involving more intensive dialysis, correction of hyperglycemia with insulin therapy, adequate hydration, and symptomatic therapy for the movement disorder.

Neuroimaging findings included bilateral BG hypodensities on CT ($n = 22$), bilateral BG hypointensities on magnetic resonance imaging (MRI) T1WI with corresponding T2WI hyperintensities, and hyperintensities in the corresponding regions on diffusion-weighted imaging (DWI) and on apparent diffusion coefficient (ADC) sequences. Seven patients had positron emission tomography (PET)/single photon emission computed tomography (SPECT) imaging, which showed hypoperfusion in the BG ($n = 4$). Two patients’ magnetic resonance spectroscopy (MRS) findings showed a low N-acetyl aspartate ratio (NAA) in the BG; one also showed an elevated lactate peak.

Clinical outcome data were available for 55 patients; 17 (30.9%) had complete resolution of the movement disorder (parkinsonism: $n = 7$; chorea: $n = 10$), while 38 (69.1%) had incomplete resolution (parkinsonism: $n = 25$; chorea: $n = 13$). Complete resolution was more frequently observed with chorea than parkinsonism (43.5% vs. 21.9%; $p = 0.09$). Radiological follow-up was available for 41 patients, with complete resolution in 14 patients (34.1%), while 27 patients showed incomplete resolution (65.9%) (Table 1).

Table 1. Summary of study characteristics of 72 patients with ESKD and acute movement disorder

Characteristic	Value
Age (yr)	57 (35–82)
Ethnicity	
Asian	43
Caucasian	6
Hispanic	3
Not specified	20
Premorbid/comorbid	
DM	30 (41.7)
DM, hypertension	10 (13.9)
DM, hypertension, coronary heart disease	3 (4.2)
Hypertension	2 (2.8)
DM, hypertension, ischemic heart disease, lacunar infarct	1 (1.4)
DM, hypertension, stroke	1 (1.4)
DM, hypertension, seizures	1 (1.4)
DM, hypertension, hypercholesterolemia	1 (1.4)
DM, hypertension, anemia	1 (1.4)
DM, hypertension, schizoaffective disorder, polysubstance abuse in remission	1 (1.4)
DM, hypertension, peripheral vascular disease, hypothyroidism, sarcoidosis	1 (1.4)
DM, hypertension, hypercholesterolemia, depression, hypercalcemia, submandibular and perihilar lymphadenopathy, sarcoidosis, hyperparathyroidism	1 (1.4)
DM, coronary disease	1 (1.4)
Hypertension, congenital renal agenesis	1 (1.4)
N/R	17 (23.6)
Duration of dialysis (yr, range)	0–20
Acute movement disorder	
Parkinsonism	29 (40.3)
Chorea	18 (25.0)
Parkinsonism, dysarthria, dysphagia	4 (5.6)
Chorea, dysarthria	4 (5.6)
Parkinsonism, dysarthria	3 (4.2)
Parkinsonian gait, dysarthria	2 (2.8)
Dystonia	2 (2.8)
Dyskinesia	1 (1.4)
Chorea, parkinsonism	1 (1.4)
Chorea, restless leg syndrome	1 (1.4)
Chorea, dyskinesia	1 (1.4)
Orolingual and facial dyskinesias, parkinsonian gaits, dysarthria, dysphagia	1 (1.4)
Parkinsonian gait	1 (1.4)
Generalized dyskinesia, ataxia, dysarthria	1 (1.4)
N/R	3 (4.2)
Radiological findings	
PET/SPECT	
Hypoperfusion in bilateral basal ganglia	1 (1.4)
Hyperperfusion in bilateral basal ganglia	1 (1.4)

Table 1. Summary of study characteristics of 72 patients with ESKD and acute movement disorder (continued)

Characteristic	Value
Hypoperfusion in bilateral striatum	1 (1.4)
Hypoperfusion in bilateral putamen, right caudate, bilateral occipital cortex, right frontal cortex	1 (1.4)
Hypoperfusion in putamen, left caudate, bilateral lateral frontal cortex	1 (1.4)
Normal	2 (2.8)
N/A	65 (90.3)
CT	
Bilateral basal ganglia hypodensity	14 (19.4)
Bilateral lenticular nuclei hypodensity	3 (4.2)
Bilateral basal ganglia hypodensity with surrounding oedema	1 (1.4)
Bilateral basal ganglia and thalami hypodensity	1 (1.4)
Bilateral lenticular nuclei hypodensity with mass effect on right caudate nucleus	1 (1.4)
Bilateral basal ganglia, thalamus, midbrain hypodensity	1 (1.4)
Bilateral putamen, globus pallidus hypodensity	1 (1.4)
Right lenticular nucleus and right caudate head	1 (1.4)
Right putamen	1 (1.4)
Striatum	1 (1.4)
Normal	5 (6.9)
N/R	9 (12.5)
N/A	33 (45.8)
Magnetic resonance imaging	
Bilateral basal ganglia atrophy	36 (50.0)
Bilateral putamen and global pallidus atrophy	7 (9.7)
Bilateral lenticular nuclei atrophy	2 (2.8)
Bilateral caudate and lenticular nuclei atrophy	4 (5.6)
Bilateral basal ganglia and thalami	2 (2.8)
Bilateral striatum atrophy	1 (1.4)
Right basal ganglia atrophy	1 (1.4)
Right lentiform nucleus, left putamen and right occipital lobe	1 (1.4)
Right lentiform nucleus	1 (1.4)
Right putamen	1 (1.4)
Striatum	1 (1.4)
Bilateral caudate, lentiform nucleus, frontal and temporal regions	1 (1.4)
Age-related atrophy	1 (1.4)
Normal	1 (1.4)
N/R	7 (9.7)
N/A	5 (6.9)
Magnetic resonance spectroscopy	
Low N-acetyl-aspartate, presence of lactate in left basal ganglia	1 (1.4)
Low N-acetyl aspartate in bilateral basal ganglia	1 (1.4)
N/A	70 (97.2)

Table 1. Summary of study characteristics of 72 patients with ESKD and acute movement disorder (continued)

Characteristic	Value
Clinical course	
Partial recovery	28 (38.9)
Complete recovery	20 (27.8)
No improvement	15 (20.8)
Near complete recovery	5 (6.9)
N/R	4 (5.6)
Radiological course	
Partial resolution	18 (25)
Complete resolution	14 (19.4)
No resolution	6 (8.3)
Near complete resolution	3 (4.2)
N/R	14 (19.4)
N/A	17 (23.6)

Data are represented as median (range) or *n* (%). ESKD, end-stage kidney disease; DM, diabetes mellitus; N/R, not reported; N/A, not applicable; PET, positron emission tomography; SPECT, single photon emission computed tomography.

Case series

Case 1

A 49-year-old Malay man with T2DM and hypertension for 20 years and ESKD on regular hemodialysis for ten years presented with a three-month history of generalized ‘involuntary movements’ that was acute in onset. The movements worsened when he was stressed or performed specific tasks and affected his daily routine and sleep. There was no family history of similar illnesses or neurological disorders or history of hyponatremia (or rapid correction thereof). Examination revealed generalized chorea predominantly affecting his upper limbs and face, which worsened upon action and speaking. The rest of the neurological examination was normal. The Montreal Cognitive Assessment score was 23/30 (primary school education). The urea level was 11.5 mmol/L, serum creatinine level was 634 μmol/L, and HbA1C was 6.0%. Antinuclear antibody, anti-dsDNA, lupus anticoagulant and anti-cardiolipin antibodies, serum ceruloplasmin, manganese, and tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9, prostate-specific antigen, and alpha fetoprotein) were negative or within the normal range. Brain MRI showed symmetrical hyperintense lesions in the bilateral lentiform nuclei on T2WI and fluid-attenuated inversion recovery (FLAIR) (Figure 1A-C). MRA of the cerebral arteries showed right middle cerebral artery atherosclerosis (not shown). The dialysis regimen was optimized by his nephrologist, with daily dialysis and high-flux dialyzers to improve dialysis efficiency. Trials of medications including haloperidol (10 mg, bid), clonazepam (2 mg, bid), tetrabenazine (25 mg, bid), and amantadine




Figure 1. A 49-year-old man with end-stage kidney disease (ESKD) on hemodialysis for 10 years presented with generalized involuntary movements (case 1). MRI of the brain in axial T1-weighted (A), T2-weighted (B), and fluid-attenuated inversion recovery (FLAIR) (C) images. Symmetrical signal abnormalities in the bilateral lentiform nuclei, returning low signal intensity on the T1-weighted image and high signal intensities on the T2-weighted and FLAIR images. The symmetrical T1 hyperintense signals in the globus pallidi most likely represents calcification. A 43-year-old man with ESKD on regular hemodialysis presented with generalized body weakness and progressive slowness in movement and hypophonia (case 2). The unenhanced CT of the brain (D) reveals a symmetrical hypodensity in the lentiform nuclei. A 71-year-old man with ESKD on regular hemodialysis presented with bilateral choreiform movements (case 4). Magnetic resonance imaging of the brain in axial T1-weighted (E), T2-weighted (F), and FLAIR (G) images demonstrate abnormalities in the bilateral lentiform nuclei returning low signal intensity on the T1-weighted image and high signal intensities on the T2-weighted and FLAIR images.

(50 mg, bid) resulted in only minimal improvement despite multiple adjustments.

Case 2

A 43-year-old Malay man with long-standing T2DM, hypertension, and ESKD on regular hemodialysis for three months presented with a three-month history of generalized body weakness and progressive slowness in movement and hypophonia. He required a walking frame to ambulate at home. There was no history of recurrent falls, memory disturbances, or urinary incontinence. Physical examination revealed bilateral cogwheel rigidity, bradykinesia, and intermittent resting tremor of the left hand. His medications included amlodipine, perindopril, clopidogrel, sitagliptin, frusemide, and calcium carbonate. Unenhanced CT of the brain showed symmetrical hypodensities in the bilateral BG (Figure 1D). Blood urea and serum creatinine levels were not available as they were assessed in another center and were not available during the initial consultation. Following the initial consultation, the patient failed to return for subsequent

follow-up. His family members provided a recent update that the patient had passed away two years after his initial visit due to an unrelated cause.

Case 3

A 68-year-old Indian man was diagnosed with T2DM, hypertension, and ESKD. He had been on regular hemodialysis since 2015 and presented in June 2018 for 'lack of strength' in his legs. He also complained of deterioration in the two months preceding his clinic visit, which led to the use of a wheelchair. There was no history of urinary symptoms, memory problems, or falls. On examination, there was hypomimia, jaw tremor, bradykinesia on finger taps and generalized rigidity consistent with parkinsonism. His renal profile showed elevated blood urea (18.8 mmol/L) and serum creatinine (914.8 $\mu\text{mol/L}$) levels. He was initiated on levodopa with modest improvement in his bradykinesia. Brain CT showed symmetrical hypodensities within the bilateral BG regions.

Case 4

A 71-year-old Indian man with hypertension and ESKD on regular hemodialysis at another center for four years presented with a three-day history of bilateral generalized choreiform movements involving the tongue, which caused difficulty ambulating and eating. He had received the Comirnaty vaccine (Pfizer-BioNTech) two weeks prior to his presentation. He also complained of fatigue, vomiting, and loss of appetite three weeks prior to presentation. On examination, there was moderate to severe generalized severe chorea, which also involved his tongue. His blood urea level was 20 mmol/L, and serum creatinine level was 1,000 μmol/L (one day after hemodialysis). Thyroid function test, serum ammonia, liver function test, diabetic screen, erythrocyte sedimentation rate, C-reactive protein, lupus screen, and anemia screen were normal or negative. Brain MRI showed bilateral lentiform hyperintensity on T2-weighted MRI and FLAIR (Figure 1E-G). He was treated with oral sulpiride and underwent another hemodialysis the same day. After dialysis, the chorea was less severe. EEG was normal. He had no further choreiform movements by the 3rd day.

DISCUSSION

We reported four ESKD patients with acute/subacute movement disorders associated with bilateral BG lesions and systematically reviewed 72 such cases from its initial description in 1998. Parkinsonism was the most common movement disorder, followed by chorea. The radiological findings were relatively homogenous with symmetrical bilateral BG lesions on CT and MRI,³ with DWI and ADC hyperintensities indicating a possible vasogenic origin. Complete clinical resolution occurred in 30.9% of the patients, while radiological resolution occurred in only 34.1% of the patients, suggesting that this syndrome may be fully reversible, although we are unable to determine the predictors for full recovery based on this review. Recovery was associated with more intensive dialysis and appropriate management of the movement disorder. The patients presenting with chorea were more likely to fully recover than those with parkinsonism.

The underlying pathogenesis of this syndrome remains unclear. T2DM, hypertension, and ESKD may collectively lead to metabolic acidosis, oxidative stress, and microvascular changes, increasing the risk of ischemic damage to the BG. In support of this notion, MRS findings showed reduced metabolism,^{4,5} and PET/SPECT scans showed hypoperfusion⁶⁻⁹ within the BG. The presence of a lactate peak on MRS implied the possibility of selective mitochondrial dysfunction within the BG.¹⁰ The abrupt onset and spontaneous recovery of the movement disorder in some patients suggested that acute ischemia may be the final in-

sult.¹¹ Conversely, chronic and continual metabolic derangement in severe ESKD may lead to permanent damage to the BG structures,¹² which could explain the lack of clinical improvement with dialysis in some patients. A recent review suggested manganese toxicity as a cause of BG lesions in ESKD patients with parkinsonism.¹³ However, only the patient in Case 1 had manganese levels tested, which were within the normal range.

Slightly more than half of the patients identified by this review were Asians. It is unclear whether this syndrome is more prevalent among Asians, similar to nonketotic hyperglycemia-induced chorea (NKHC), which also affects BG structures.¹⁴ While this observation could be entirely due to higher reporting by researchers from Asian countries, it also raises the question of whether Asians are generally more predisposed toward metabolic BG insults.

Limitations and conclusion

There are several limitations in this review. First, clinical and radiological outcome measures were not consistently reported. Second, we were unable to determine the long-term outcome, as no prospective follow-up findings were reported in most of the reports. Nevertheless, we believe this review adds to the expanding literature on this syndrome and points toward the possibility of endogenous susceptibility among specific individuals. Future studies should investigate the long-term outcomes of this condition and determine the underlying predisposing causes.

Supplementary Materials

The online-only Data Supplement is available with this article at <https://doi.org/10.14802/jmd.21185>.

Conflicts of Interest

The authors have no financial conflicts of interest.

Funding Statement

None

Author Contributions

Conceptualization: Nurul Husna Baharudin, Norlinah Mohamed Ibrahim. Data curation: Kah Hui Yap, Nurul Husna Baharudin. Formal analysis: Kah Hui Yap. Investigation: Kah Hui Yap, Nurul Husna Baharudin. Methodology: Kah Hui Yap, Nurul Husna Baharudin. Project administration: Kah Hui Yap, Nurul Husna Baharudin. Resources: Kah Hui Yap. Supervision: Norlinah Mohamed Ibrahim. Validation: Norlinah Mohamed Ibrahim. Visualisation: all authors. Writing—original draft: Kah Hui Yap, Nurul Husna Baharudin. Writing—review & editing: Abdul Halim Abdul Gafar, Rabani Remli, Shen-Yang Lim, Wan Asyraf Wan Zaidi, Shahrlul Azmin, Shahizon Azura Mohamed Mukari, Raihanah Abdul Khalid, Norlinah Mohamed Ibrahim.

ORCID iDs


Kah Hui Yap	https://orcid.org/0000-0002-7877-2997
Nurul Husna Baharudin	https://orcid.org/0000-0003-0761-8404
Abdul Halim Abdul Gafar	https://orcid.org/0000-0003-3950-2844
Rabani Remli	https://orcid.org/0000-0003-3988-7609
Shen-Yang Lim	https://orcid.org/0000-0002-6942-2522

Wan Asyraf Wan Zaidi <https://orcid.org/0000-0002-0880-3591>
 Shahrlul Azmin <https://orcid.org/0000-0003-4102-7915>
 Shahizon Azura Mohamed Mukari <https://orcid.org/0000-0002-5520-9632>
 Raihanah Abdul Khalid <https://orcid.org/0000-0002-5375-5090>
 Norlinah Mohamed Ibrahim <https://orcid.org/0000-0002-6684-7488>

REFERENCES

1. Bhagwan S, Marais S, Bhagwan B, Bhigjee AI. Reversible syndrome of extrapyramidal movement disorders with bilateral basal ganglia lesions in uremia: a case series and review of the literature. *Afr J Neurol Sci* 2018; 37:47-51.
2. Hamed S, Mohamed K, Abd Elhameed S, Moussa E, Abozaid H, Lang A, et al. Movement disorders due to selective basal ganglia lesions with uremia. *Can J Neurol Sci* 2020;47:350-365.
3. Van Cauter S, Severino M, Ammendola R, Van Berkel B, Vavro H, van den Hauwe L, et al. Bilateral lesions of the basal ganglia and thalami (central grey matter)-pictorial review. *Neuroradiology* 2020;62:1565-1605.
4. Dicuonzo F, Di Fede R, Salvati A, Palma M, de Mari M, Baldassarre GD, et al. Acute extrapyramidal disorder with bilateral reversible basal ganglia lesions in a diabetic uremic patient: diffusion-weighted imaging and spectroscopy findings. *J Neurol Sci* 2010;293:119-121.
5. Tajima Y, Mito Y, Yanai M, Fukazawa Y. Unusual basal ganglia lesions in a diabetic uraemic patient proven to be demyelination: first pathological observation. *BMJ Case Rep* 2012;2012:bcr2012006522.
6. Choi EK, Oh JK, Chung YA, Song IU. Brain SPECT and MRI findings in a uremic patient with parkinsonism. *Clin Nucl Med* 2015;40:e453-e454.
7. Ishii K, Ishii K, Shioya A, Nemoto K, Tamaoka A. Decreased dopamine transporter and receptor ligand binding in Parkinsonism with diabetic uremic syndrome. *Ann Nucl Med* 2016;30:320-324.
8. Lee PH, Shin DH, Kim JW, Song YS, Kim HS. Parkinsonism with basal ganglia lesions in a patient with uremia: evidence of vasogenic edema. *Parkinsonism Relat Disord* 2006;12:93-96.
9. Wang HC, Hsu JL, Shen YY. Acute bilateral basal ganglia lesions in patients with diabetic uremia: an FDG-PET study. *Clin Nucl Med* 2004;29: 475-478.
10. Lunsing RJ, Strating K, de Koning TJ, Sijens PE. Diagnostic value of MRS-quantified brain tissue lactate level in identifying children with mitochondrial disorders. *Eur Radiol* 2017;27:976-984.
11. Robbins NM, Swanson RA. Opposing effects of glucose on stroke and reperfusion injury: acidosis, oxidative stress, and energy metabolism. *Stroke* 2014;45:1881-1886.
12. Cirillo G, Cirillo M, Panetsos F, Virtuoso A, Papa M. Selective vulnerability of basal ganglia: insights into the mechanisms of bilateral striatal necrosis. *J Neuropathol Exp Neurol* 2019;78:123-129.
13. Safarpour Y, Vaziri ND, Jabbari B. Movement disorders in chronic kidney disease—a descriptive review. *J Stroke Cerebrovasc Dis* 2021;30:105408.
14. Oh Y, Lee KY, Im JH, Lee MS. Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study: a meta-analysis of 53 cases including four present cases. *J Neuro Sci* 2002;200:57-62.

Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders	Supplementary Table 1. Characteristics of end-stage kidney disease patients with acute movement disorders
Study/country	Main clinical characteristics	PET/SPECT	CT	MRI	Clinical course	Radiological course	
Bhagwan et al. ¹ (2018)	Age: case 1-4, 44-68 years Ethnicity: Indian Premorbid/comorbid: DM (n=6), hypertension (n=1) Duration of (ES/RD): case 1-7, 8-75 days Duration of dialysis prior to AMD: 1-2 years Type of AMD: Parkinsonism (n=6), chorea (n=1), dystonia (n=1)	N/A	Bilateral basal ganglia hypodensities (n=2)	Hypointensity in bilateral basal ganglia in T1; hyperintensity in same regions in T2-weighted MRI (n=6) Vasogenic and cytotoxic edema on DWI and ADC	Levodopa for parkinsonism, haloperidol for chorea, and combination of risperidone and clonazepam for dystonia Two patients showed complete recovery Five patients showed partial recovery One patient had no improvement	Complete resolution (n=2)	
Chen et al. ² (2015)Taiwan	Age: 56 years Ethnicity: not specified Premorbid/comorbid: DM Duration of (ES/RD): 10 years Duration of dialysis prior to AMD: 1 years Type of AMD: dyskinesia	N/A	Bilateral basal ganglia hypodensities	Hypointensity in bilateral caudate and lentiform nuclei in T1; hyperintensity in same regions and external capsules, thalami, and periventricular WM in T2-weighted MRI	Regular hemodialysis and haloperidol resulted in complete resolution	N/A	
Choi et al. ³ (2016)Korea	Age: 60 years Ethnicity: Korean Premorbid/comorbid: DM Duration of (ES/RD): 6 years Duration of dialysis prior to AMD: 2 years Type of AMD: Parkinsonism	SPECT: hyperperfusion in bilateral basal ganglia	N/A	Hyperintensity in bilateral lentiform nuclei (basal ganglia) in T2-weighted MR and ADC	Partial improvement with dialysis (stabilization of urea nitrogen [BUN] and creatinine levels)	N/R	
Cupidi et al. ⁴ (2006)Italy	Age: 68 years Ethnicity: Caucasian Premorbid/comorbid: DM, hypertension, coronary heart disease Duration of (ES/RD): 10 years Duration of dialysis prior to AMD (years): N/A Type of AMD: Parkinsonism	N/A	Bilateral basal ganglia hypodensity	Enhancement in bilateral caudate and lentiform nuclei in T1; hyperintensity in same regions and external capsules, thalami, and periventricular WM in T2-weighted MRI	Complete recovery with insulin therapy (decreased blood creatinine level and blood glucose was well controlled)	N/R	
Diconzo et al. ⁵ (2010)Italy	Age: 51 years Ethnicity: Caucasian Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): NR Type of AMD: chorea	N/A	Bilateral lentiform nuclei hypodensity	Hyperintensity in bilateral basal ganglia (sparing caudate) in T1; hyperintensity in same regions in T2-weighted MR and FLAIR; hyperintensity with high ADC on same regions in DWI; decreased N-acetylaspartate and presence of lactate in left basal ganglia lesion on Proton	Partial improvement with olanzapine with relapse-remitting course	N/R	
Fabiani et al. ⁶ (2013)Brazil	Age: 60 years Ethnicity: not specified Premorbid/comorbid: N/R Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): NR Type of AMD: Parkinsonism	N/A	N/A	Hyperintensity in bilateral basal ganglia (caudate, putamen, thalamus),LFS in FLAIR	Complete recovery with dialysis and levodopa/benserazide	Complete resolution	
Fernandes et al. ⁷ (2015)Brazil	Age: 63 years Ethnicity: not specified Premorbid/comorbid: N/R Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): NR Type of AMD: Parkinsonism	N/A	Bilateral basal ganglia hypodensities	Vasogenic edema with T2/fluid-attenuated inversion recovery hyperintensity in the basal ganglia compatible with the LFS	N/R	N/A	
Hamed et al. ⁸ (2020)Egypt	Age: Case 1: 58 years Case 2: 62 years Case 3: 65 years Case 4: 60 years Case 5: 58 years Case 6: 60 years Case 7: 60 years Premorbid/comorbid: Case 1: DM Case 2: DM, hypertension Case 3: hypertension and congenital renal agenesis Case 4: DM Case 5: DM, hypertension Case 6: hypertension Duration of (ES/RD): Case 1: 3 years Case 2: 5 years Case 3: 2 years Case 4: 8 years Case 5: 3 years Case 6: 6 years Duration of dialysis prior to AMD: Case 1: 1 years Case 2: N/A Case 3: N/A Case 4: 2 years Case 5: N/A Case 6: 3 years Case 7: N/A Type of AMD: Case 1: Parkinsonism Case 2: chorea Case 3: Parkinsonism Case 4: Parkinsonism Case 5: Parkinsonism Case 6: dystonia	N/A	Case 3: unremarkable Case 4: normal Case 6: hypodensity in the right putamen	Case 1: hypointensity in the right lentiform nucleus, left putamen, and the right occipital lobe in T1; hyperintensity in the same regions in T2 and DWI Case 2: hypointensity in the putamen and globus pallidus externa in T1; hyperintensity in the same regions in T2 and DWI Case 3: hypointensity in the bilateral basal ganglia and thalami in T1; hyperintensity in the same regions in T2 and DWI Case 4: hypointensity in the right putamen and globus pallidus interna in T1; hyperintensity in the same regions in T2 and DWI Case 5: hypointensity in the right lentiform nucleus in T1; hyperintensity in the same regions in T2 and DWI Case 6: hypointensity in the same regions in T2 and DWI Case 7: hyperintensity in the same regions in T2 and DWI	Case 1: no recovery Case 2: no recovery Case 3: no recovery Case 4: partial improvement Case 5: no recovery Case 6: no recovery	Case 1: complete resolution Case 2: complete resolution Case 3: complete resolution Case 4: N/A Case 5: near complete resolution Case 6: N/A	
Ishii et al. ⁹ (2016)Japan	Age: 77 years Ethnicity: Japanese Premorbid/comorbid: DM Duration of (ES/RD): 4 years Duration of dialysis prior to AMD: 4 years Type of AMD: Parkinsonism	PET: hyperperfusion in bilateral striatum	N/A	Hypointensity/edematous in bilateral striatum (especially putamen) Hyperintensity in same regions in T2-weighted MRI; cystic lesion in bilateral putamen (vacuolated changes following focal necrosis)	No clinical improvement with levodopa/benserazide	N/R	
Kim et al. ¹⁰ (2006)Korea	Age: 55 years Ethnicity: Asian Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD: 4 years Type of AMD: Parkinsonism	N/A	N/A	Hypointensity/edema in bilateral basal ganglia Hyperintensity in same regions in T2-weighted MRI; cystic lesion in bilateral putamen (vacuolated changes following focal necrosis)	Partial recovery	Partial resolution	
Kim et al. ¹¹ (2015)Korea	Age: Case 1: 45 years Case 2: 56 years Case 3: 56 years Case 4: 35 years Case 5: 48 years Ethnicity: Korean Premorbid/comorbid: Case 1-5: DM Duration of (ES/RD): 9.5-20 years Duration of dialysis prior to AMD (years): NR Type of AMD: chorea	N/A	Case 1: hypointensity in bilateral putamen and globus pallidus Case 2: N/A Case 3: not contributable Case 4: N/A Case 5: N/A	Case 1: DWI hyperintensity in the bilateral putamen and globus pallidus Case 2: hypointensity in T1; hyperintensity in T2 in the same regions with swelling Case 3: not contributable Case 4: hyperintensity in the center and hypointensity in the periphery in T1; hyperintensity in the same regions in T2 with swelling Case 5: hypointensity in T1; hyperintensity in T2 in the same regions	Case 1: partial recovery Case 2: complete recovery Case 3: partial recovery Case 4: partial recovery Case 5: complete recovery	Case 1: N/A Case 2: no resolution Case 3: N/A Case 4: N/A Case 5: no resolution	
Kiryak K, Vlahi A (2008) United States	Age: 71 years Ethnicity: Hispanic Premorbid/Comorbid: DM, hypertension, hypercholesterolemia, depression, hypercalcemia, submandibular and perilar lymphadenopathy, sarcoidosis, hyperparathyroidism Duration of (ES/RD): 3 years Duration of dialysis prior to AMD: 3 years Type of AMD: chorea	N/A	N/A	Hyperintensity in bilateral putamen and globus pallidus on T2-weighted MR and FLAIR	Complete recovery with conservative management and rehabilitation	Complete resolution	
Kumar and Goyal ¹² (2010) United States	Age: 48 years Ethnicity: not specified Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): NR Type of AMD: N/R	N/A	Bilateral basal ganglia, thalamus, and midbrain hypodensity	Hyperintensity in bilateral basal ganglia (caudate, putamen, thalamus),LFS, midbrain, and mesial temporal lobes on T2/FLAIR	N/R	Complete resolution	
Kuppachi et al. ¹³ (2013) United States	Age: 58 years Ethnicity: Hispanic Premorbid/comorbid: DM, hypertension, peripheral vascular disease, hyothyroidism, sarcoidosis Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD: 4 years Type of AMD: chorea	N/A	Bilateral basal ganglia hypodensity	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2	Partial improvement with conservative management	N/A	
Lee et al. ¹⁴ (2007)Korea	Age: Case 1-4, 44-68 years Ethnicity: Korean Premorbid/comorbid: DM Duration of (ES/RD): 0.5-2 years Duration of dialysis prior to AMD (years): NR Type of AMD: chorea, dysarthria	N/A	Bilateral basal ganglia hypodensity	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2 Increased ADC in DWI	Partial improvement with dialysis and supportive management	Partial resolution	
Lee et al. ¹⁵ (2006)Korea	Age: 48 years Ethnicity: not specified Premorbid/comorbid: DM Duration of (ES/RD): 15 years Duration of dialysis prior to AMD: 4 years Type of AMD: Parkinsonism	SPECT: hyperperfusion in bilateral basal ganglia	N/A	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2 Increased ADC in DWI	Partial improvement with dialysis	Complete resolution	
Li et al. ¹⁶ (2008)Australia	Age: 77 years Ethnicity: Caucasian Premorbid/comorbid: DM, hypertension Duration of (ES/RD): 5 years Duration of dialysis prior to AMD: 6 years Type of AMD: Parkinsonism	N/A	Bilateral basal ganglia (lentiform and caudate nuclei) hypodensity	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2 and FLAIR Hyperintensity in lentiform nuclei and caudate nuclei head in DWI	No clinical improvement with dialysis	No resolution	
Lin ¹⁷ (2011)Taiwan	Age: Case 1: 57 years Case 2: 82 years Ethnicity: Chinese Premorbid/comorbid: Case 2: DM, hypertension Case 2: DM, hypertension, ischemic heart disease, lacunar infarct Duration of (ES/RD): Case 1: 5 years Case 2: 2 years Duration of dialysis prior to AMD: Case 1: 2 years Case 2: N/R Type of AMD: Case 1: chorea Case 2: chorea	N/A	N/A	Case 1: hypointensity in bilateral basal ganglia in T1; hyperintensity in same regions in T2, FLAIR, and DWI (low ADC) Case 2: hypointensity in bilateral basal ganglia in T1; hyperintensity in same regions in T2, FLAIR, and DWI (low ADC)	Case 1: complete recovery with dialysis and supportive management Case 2: complete recovery with haloperidol	Case 1: complete resolution Case 2: complete resolution	
Lizarraga et al. ¹⁸ (2017) United States	Age: 47 years Ethnicity: Asian Premorbid/comorbid: DM Duration of (ES/RD): 2 years Duration of dialysis prior to AMD (years): NR Type of AMD: chorea and parkinsonism	N/A	Striatal vasogenic edema surrounding areas of central cytotoxicity, blood extravasation and hyperdense lenticostratial arteries in the striatopallidum junctions	Striatal vasogenic edema surrounding areas of central cytotoxicity, blood extravasation and hyperdense lenticostratial arteries in the striatopallidum junctions	Near complete recovery	Partial resolution	
Mahajan et al. ¹⁹ (2014)India	Age: 52 years Ethnicity: Indian Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD: 4 years Type of AMD: chorea	N/A	N/A	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2, FLAIR, and ADC	Complete recovery	N/A	
Mehta et al. ²⁰ (2017)India	Age: 57 years Ethnicity: not specified Premorbid/comorbid: DM Duration of (ES/RD): 4 years Duration of dialysis prior to AMD (years): N/A Type of AMD: Parkinsonism	N/A	N/A	Diffuse oedematous symmetrical T2 and fluid-attenuated inversion recovery hyperintensities in bilateral caudate and lentiform nuclei with mild diffusion restriction	Complete resolution with daily haemodialysis	Near complete resolution	
Novais et al. ²¹ (2012)Portugal	Age: 63 years Ethnicity: Caucasian Premorbid/comorbid: DM, hypertension, schizoaffective disorder, and polysubstance abuse in remission Duration of (ES/RD): 3 years Duration of dialysis prior to AMD (years): 3 years Type of AMD: Parkinsonism	N/A	N/A	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2 and FLAIR	Complete recovery	N/R	
Ozben et al. ²² (2011)Turkey	Age: 54 years Ethnicity: not specified Premorbid/comorbid: DM Duration of (ES/RD): 5 years Duration of dialysis prior to AMD: 3 years Type of AMD: Parkinsonism	N/A	N/A	Hypointensity in bilateral lentiform nucleus in T1 Hyperintensity in same regions in T2 and FLAIR	Complete recovery	N/A	
Park et al. ²³ (2007)Korea	Age: 68 years Ethnicity: not specified Premorbid/comorbid: DM, hypertension Duration of (ES/RD): 4 years Duration of dialysis prior to AMD: 1 years Type of AMD: chorea	N/A	N/A	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2, FLAIR, and ADC	Near complete recovery	Partial resolution	
Park et al. ²⁴ (2015)Korea	Age: 52 years Ethnicity: not specified Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): NR Type of AMD: Parkinsonism	PET: no abnormality	N/A	Hyperintensity in the bilateral basal ganglia in T2 FLAIR, DWI and ADC (LFS)	Near complete recovery without anti-Parkinson medication	Complete resolution	
Rao et al. ²⁵ (2019)India	Age: 78 years Ethnicity: Indian Premorbid/comorbid: DM, hypertension Duration of (ES/RD): 15 years Duration of dialysis prior to AMD (years): N/A Type of AMD: chorea	N/A	N/A	Age-related atrophy	Complete recovery with intravenous fluids and broad-spectrum intravenous antibiotics at doses that were modified according to renal function	N/R	
Rathi and Mudrabettu ²⁶ (2017)India	Age: 35 years Ethnicity: Indian Premorbid/comorbid: DM, hypertension Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): NR Type of AMD: N/R	N/A	Hypodensity in bilateral basal ganglia with surrounding edema	Hyperintensity in bilateral basal ganglia in T2/FLAIR with LFS	No recovery with intubation, hyperventilation, and by injecting desmethadone to reduce the intracranial pressure with intensive dialysis support	No resolution	
Rozenberg and Telman ²⁷ (2012)Israel	Age: 64 years Ethnicity: not specified Premorbid/comorbid: DM, hypertension, dyslipidaemia Duration of (ES/RD): NR Duration of dialysis prior to AMD: NR Type of AMD: chorea	N/A	Hypodensities in the bilateral basal ganglia	N/A	Complete recovery with tetrabenazine	Complete resolution	
Shin et al. ²⁸ (2008)Korea	Age: 44 years Ethnicity: not specified Premorbid/comorbid: DM, depression Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD (years): N/A Type of AMD: chorea & restless leg syndrome	N/A	N/A	Hyperintensity in bilateral basal ganglia and right thalamus in T2/FLAIR	Partial recovery	Partial resolution	
Spertling and Bhawanisingh ²⁹ (2018) United States	Age: 62 years Ethnicity: Caucasian Premorbid/comorbid: DM, hypertension, hypercholesterolemia Duration of (ES/RD): 2 years Duration of dialysis prior to AMD (years): N/A Type of AMD: chorea	N/A	Hyperintensity in the right lentiform nucleus and right caudate head	Hyperintensity in the caudate nucleus portion of the right basal ganglia in T1 and T2 Postcontrast MRI of the brain showed no abnormal enhancement excluding the possibility of a mass lesion No abnormal restricted diffusion in the right basal ganglia in DWI which excluded ischemia	Complete recovery with home insulin regimen with the addition of inpatient corrective coverage. This included Lantus 20 units every morning and 10 units of Novolog 3 times a day with meals	N/R	
Tajima et al. ³⁰ (2012)Japan	Age: 64 years Ethnicity: Caucasian Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD: 0.25 years Type of AMD: Parkinsonism	N/A	N/A	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2 and ADC in DWI Low N-acetyl aspartate in same areas in Proton MRS	Partial improvement with dialysis and supportive management	Partial resolution	
Wali et al. ³¹ (2011)India	Age: 67 years Ethnicity: Indian Premorbid/comorbid: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD: 4 years Type of AMD: dyskinesia and chorea	N/A	N/A	Hypointensity in bilateral basal ganglia in T1 Hyperintensity in same regions in T2 and FLAIR Hyperintensity in ADC in DWI	Complete recovery with increasing frequency of dialysis	Near complete resolution	
Wang et al. ³² (1998)Taiwan	Age: Case 1: 50 years Case 2: 49 years Case 3: 49 years Ethnicity: Chinese Premorbid/comorbid: Case 1: DM, hypertension Case 2: DM Case 3: DM Duration of (ES/RD) (years): NR Duration of dialysis prior to AMD: Case 1: N/R Case 2: 0.67 years Case 3: N/R Type of AMD: Parkinsonism	N/A	Case 1: bilateral lentiform nuclei hypodensity Case 2: N/A Case 3: basal ganglia and part of bilateral thalami hypodensity	Case 1: hypointensity in bilateral lentiform nuclei in T1; hyperintensity in same regions in T2 Case 2: hypointensity in bilateral lentiform nuclei in T1; hyperintensity in same regions in T2 Case 3: hypointensity in bilateral basal ganglia and part of bilateral thalami in T1; hyperintensity in same regions in T2	Case 1: partial improvement with oral biperiden and clonazepam Case 2: partial improvement without specific treatment Case 3: partial improvement with dialysis	Case 1: NR Case 2: NR Case 3: partial resolution	
Wang and Cheng ³³ (2003)Taiwan	Age: Case 1: 61 years Case 2: 45 years Case 3: 60 years Case 4: 56 years Case 5: 63 years Case 6: 52 years Case 7: 59 years Case 8: 67 years Case 9: 67 years Case 10: 50 years Case 11: 49 years Case 12: 49 years Case 13: 51 years Case 14: 51 years Case 15: 52 years Case 16: 52 years Case 17: 52 years Case 18: 52 years Case 19: 52 years Case 20: 52 years Case 21: 52 years Case 22: 52 years Case 23: 52 years Case 24: 52 years Case 25: 52 years Case 26: 52 years Case 27: 52 years Case 28: 52 years Case 29: 52 years Case 30: 52 years Case 31: 52 years Case 32: 52 years Case 33: 52 years Case 34: 52 years Case 35: 52 years Case 36: 52 years Case 37: 52 years Case 38: 52 years Case 39: 52 years Case 40: 52 years Case 41: 52 years Case 42: 52 years Case 43: 52 years Case 44: 52 years Case 45: 52 years Case 46: 52 years Case 47: 52 years Case 48: 52 years Case 49: 52 years Case 50: 52 years Case 51: 52 years Case 52: 52 years Case 53: 52 years Case 54: 52 years Case 55: 52 years Case 56: 52 years Case 57: 52 years Case 58: 52 years Case 59: 52 years Case 60: 52 years Case 61: 52 years Case 62: 52 years Case 63: 52 years Case 64: 52 years Case 65: 52 years Case 66: 52 years Case 67: 52 years Case 68: 52 years Case 69: 52 years Case 70: 52 years Case 71: 52 years Case 72: 52 years Case 73: 52 years Case 74: 52 years Case 75: 52 years Case 76: 52 years Case 77: 52 years Case 78: 52 years Case 79: 52 years Case 80: 52 years Case 81: 52 years Case 82: 52 years Case 83: 52 years Case 84: 52 years Case 85: 52 years Case 86: 52 years Case 87: 52 years Case 88: 52 years Case 89: 52 years Case 90: 52 years Case 91: 52 years Case 92: 52 years Case 93: 52 years Case 94: 52 years Case 95: 52 years Case 96: 52 years Case 97: 52 years Case 98: 52 years Case 99: 52 years Case 100: 52 years Case 101: 52 years Case 102: 52 years Case 103: 52 years Case 104: 52 years Case 105: 52 years Case 106: 52 years Case 107: 52 years Case 108: 52 years Case 109: 52 years Case 110: 52 years Case 111: 52 years Case 112: 52 years Case 113: 52 years Case 114: 52 years Case 115: 52 years Case 116: 52 years Case 117: 52 years Case 118: 52 years Case 119: 52 years Case 120: 52 years Case 121: 52 years Case 122: 52 years Case 123: 52 years Case 124: 52 years Case 125: 52 years Case 126: 52 years Case 127: 52 years Case 128: 52 years Case 129: 52 years Case 130: 52 years Case 131: 52 years Case 132: 52 years Case 133: 52 years Case 134: 52 years Case 135: 52 years Case 136: 52 years Case 137: 52 years Case 138: 52 years Case 139: 52 years Case 140: 52 years Case 141: 52 years Case 142: 52 years Case 143: 52 years Case 144: 52 years Case 145: 52 years Case 146: 52 years Case 147: 52 years Case 148: 52 years Case 149: 52 years Case 150: 52 years Case 151: 52 years Case 152: 52 years Case 153: 52 years Case 154: 52 years Case 155: 52 years Case 156: 52 years Case 157: 52 years Case 158: 52 years Case 159: 52 years Case 160: 52 years Case 161: 52 years Case 162: 52 years Case 163: 52 years Case 164: 52 years Case 165: 52 years Case 166: 52 years Case 167: 52 years Case 168: 52 years Case 169: 52 years Case 170: 52 years Case 171: 52 years Case 172: 52 years Case 173: 52 years Case 174: 52 years Case 175: 52 years Case 176: 52 years Case 177: 52 years Case 178: 52 years Case 179: 52 years Case 180: 52 years Case 181: 52 years Case 182: 52 years Case 183: 52 years Case 184: 52 years Case 185: 52 years Case 186: 52 years Case 187: 52 years Case 188: 52 years Case 189: 52 years Case 190: 52 years Case 191: 52 years Case 192: 52 years Case 193: 52 years Case 194: 52 years Case 195: 52 years Case 196: 52 years Case 197: 52 years Case 198: 52 years Case 199: 52 years Case 200: 52 years Case 201: 52 years Case 202: 52 years Case 203: 52 years Case 204: 52 years Case 205: 52 years Case 206: 52 years Case 207: 52 years Case 208: 52 years Case 209: 52 years Case 210: 52 years Case 211: 52 years Case 212: 52 years Case 213: 52 years Case 214: 52 years Case 215: 52 years Case 216: 52 years Case 217: 52 years Case 218: 52 years Case 219: 52 years Case 220: 52 years Case 221: 52 years Case 222: 52 years Case 223: 52 years Case 224: 52 years Case 225: 52 years Case 226: 52 years Case 227: 52 years Case 228: 52 years Case 229: 52 years Case 230: 52 years Case 231: 52 years Case 232: 52 years Case 233: 52 years Case 234: 52 years Case 235: 52 years Case 236: 52 years Case 237: 52 years Case 238: 52 years Case 239: 52 years Case 240: 52 years Case 241: 52 years Case 242: 52 years Case 243: 52 years Case 244: 52 years Case 245: 52 years Case 246: 52 years Case 247: 52 years Case 248: 52 years Case 249: 52 years Case 250: 52 years Case 251: 52 years Case 252: 52 years Case 253: 52 years Case 254: 52 years Case 255: 52 years Case 256: 52 years Case 257: 52 years Case 258: 52 years Case 259: 52 years Case 260: 52 years Case 261: 52 years Case 262: 52 years Case 263: 52 years Case 264: 52 years Case 265: 52 years Case 266: 52 years Case 267: 52 years Case 268: 52 years Case 269: 52 years Case 270: 52 years Case 271: 52 years Case 272: 52 years Case 273: 52 years Case 274: 52 years Case 275: 52 years Case 276: 52 years Case 277: 52 years Case 278: 52 years Case 279: 52 years Case 280: 52 years Case 281: 52 years Case 282: 52 years Case 283: 52 years Case 284: 52 years Case 285: 52 years Case 286: 52 years Case 287: 52 years Case 288: 52 years Case 289: 52 years Case 290: 52 years Case 291: 52 years Case 292: 52 years Case 293: 52 years Case 294: 52 years Case 295: 52 years Case 296: 52 years Case 297: 52 years Case 298: 52 years Case 299: 52 years Case 300: 52 years Case 301: 52 years Case 302: 52 years Case 303: 52 years Case 304: 52 years Case 305: 52 years Case 306: 52 years Case 307: 52 years Case 308: 52 years Case 309: 52 years Case 310: 52 years Case 311: 52 years Case 312: 52 years Case 313: 52 years Case 314: 52 years Case 315: 52 years Case 316: 52 years Case 317: 52 years Case 318: 52 years Case 319: 52 years Case 320: 52 years Case 321: 52 years Case 322: 52 years Case 323: 52 years Case 324: 52 years Case 325: 52 years Case 326: 52 years Case 327: 52 years Case 328: 52 years Case 329: 52 years Case 330: 52 years Case 331: 52 years Case 332: 52 years Case 333: 52 years Case 334: 52 years Case 335: 52 years Case 336: 52 years Case 337: 52 years Case 338: 52 years Case 339: 52 years Case 340: 52 years Case 341: 52 years Case 342: 52 years Case 343: 52 years Case 344: 52 years Case 345: 52 years Case 346: 52 years Case 347: 52 years Case 348: 52 years Case 349: 52 years Case 350: 52 years Case 351: 52 years Case 352: 52 years Case 353: 52 years Case 354: 52 years Case 355: 52 years Case 356: 52 years Case 357: 52 years Case 358: 52 years Case 359: 52 years Case 360: 52 years Case 361: 52 years Case 362: 52 years Case 363: 52 years Case 364: 52 years Case 365: 52 years Case 366: 52 years Case 367: 52 years Case 368: 52 years Case 369: 52 years Case 370: 52 years Case 371: 52 years Case 372: 52 years Case 373: 52 years Case 374: 52 years Case 375: 52 years Case 376: 52 years Case 377: 52 years Case 378: 52 years Case 379: 52 years Case 380: 52 years Case 381: 52 years Case 382: 52 years Case 383: 52 years Case 384: 52 years Case 385: 52 years Case 386: 52 years Case 387: 52 years Case 388: 52 years Case 389: 52 years Case 390: 52 years Case 391: 52 years Case 392: 52 years Case 393: 52 years Case 394: 52 years Case 395: 52 years Case 396: 52 years Case 397: 52 years Case 398: 52 years Case 399: 52 years Case 400: 52 years Case 401: 52 years Case 402:						



Supplementary Figure 1. Study search per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline.